MEA and impedance measurements using the CardioExcyte 96 system

The CardioExcyte 96 system (Nanion Technologies) measures both cardiomyocyte contractility (i.e. impedance) and electrophysiology simultaneously. This easy-to-use yet robust platform is label-free with real-time analysis, enabling short (seconds) to long (days) term measurements of the effects of different compounds on cell behavior.

User guide

hiPSC-derived cardiomyocytes are optimized for use on the CardioExcyte 96 system

Human iPSC-derived cardiomyocytes in combination with the CardioExcyte 96 system enables detailed detection of potential cardioactive and proarrhythmic effects of test compounds on the contractility and electrophysiology of cardiomyocytes in a 96-well plate format.

This combination provides a highly relevant in vitro assay platform to study the cardiac safety profile of compounds during drug development.

You can find a step-by-step description on how to combine Pluricyte® Cardiomyocytes with the CardioExcyte 96 system in our User Guide.


Cardiac safety assessment using hiPSC-derived cardiomyocytes in combination with the CardioExcyte 96 system

Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology (i.e. extracellular field potential, EFP) and impedance of Pluricyte® Cardiomyocytes using the CardioExcyte 96 system. They showed expected pharmacological responses in a reproducible manner, which could be readily detected with the CardioExcyte 96 system.

Below, an example is shown of the effect of the reference compound, nifedipine.

Pharmacological response of Pluricyte® Cardiomyocytes to nifedipine

As expected, the L-type calcium channel blocker, nifedipine, induced a concentration-dependent decrease in impedance peak-amplitude (left) and in field potential duration (right) in Pluricyte® Cardiomyocytes.


Download the complete application note here: